News & Views
Graffinity Enters into Drug Discovery Collaboration with Shionogi
Aug 05 2011
Graffinity Pharmaceuticals GmbH, a member of the NovAliX group of companies, have announced that it has entered into a research collaboration with Osaka, Japan based Shionogi & Co, Ltd Under the terms of the agreement, Graffinity will receive technology access fees and payments for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target. Financial details of the transaction were not disclosed. Mathias Woker, Chief Business Officer of Graffinity, remarked:, ”We are pleased that Shionogi has chosen to collaborate with us to apply our fragment based screening platform to one of Shionogi’s high priority discovery programs. This marks our first collaboration with a leading Japanese pharmaceutical company. Our proprietary assay/label-free SPR primary screen of 24,000 fragments and 87,000 leadlike molecules is often crucial in addressing drug targets that are difficult to screen with other technologies.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia